UK +44 (0)1223 491486      USA toll free 1-866 877 2185

26 07, 2021

Qkine and Enantis sign licensing deal for hyperstable FGF2-STAB®

By |2021-07-26T08:14:57+00:00July 26th, 2021|animal-free, cellular agriculture, news, press release, protein engineering, protein science, stem cells|Comments Off on Qkine and Enantis sign licensing deal for hyperstable FGF2-STAB®

Qkine and Enantis have concluded a global licensing deal for Enantis’s patented FGF2-STAB® technology. FGF2-STAB® is a hyperstable form of FGF-2 (bFGF), a core reagent for stem cell culture. FGF2-STAB (FGF2-G3) does not degrade in culture media for enhanced weekend-free stem cell culture media and advanced chemically defined systems, such as those needed in the cultured meat industry.

12 07, 2021

mouse LIF protein vs ESGRO?

By |2021-07-13T09:31:20+00:00July 12th, 2021|#qkinetechtip, protein science, quality, resources, stem cells|Comments Off on mouse LIF protein vs ESGRO?

There is no fundamental difference between ESGRO and recombinant mouse leukaemia inhibitor factor (mLIF) protein. Both can be used for the successful maintenance of mouse embryonic stem cell (ESC) pluripotency. 10E7 units of ESGRO is equivalent to 100 µg of pure protein. Thank you to Susanne van den Brink (postdoc in Anna Bigas lab, IMIM, Barcelona) and David Turner (University of Liverpool) for sharing their resuspension protocol to prepare ESLIF media.

10 06, 2021

pep talk June 2021

By |2021-07-12T21:27:26+00:00June 10th, 2021|news, resources, stem cells|Comments Off on pep talk June 2021

June update with featured publication from Austin Smith lab, Kinoshita et al - capture of mouse and human stem cells with features of formative pluripotency; introduction to our "class of 2021" new products we've made this year; explaining pioneering proteins that bring innovative growth factors to stem cell researchers and free reconstitution solution to make lab life easy

10 03, 2021

pioneering proteins launch

By |2021-03-12T13:00:44+00:00March 10th, 2021|news, protein engineering, protein science|Comments Off on pioneering proteins launch

We are proud to launch our Pioneering Protein range! A range of modified proteins have been carefully developed by world leading academic laboratories, licenced through Cambridge Enterprise, and then manufactured to our high purity and bioactivity standards, bringing together academic innovation with high level manufacturing purity. Folloistatin-resistant activin A (FRACTA) has been developed by our [...]

8 03, 2021

Celebrating International Women’s Day 2021 with our amazing team, collaborators, customers and wider network

By |2021-03-10T14:20:30+00:00March 8th, 2021|news|Comments Off on Celebrating International Women’s Day 2021 with our amazing team, collaborators, customers and wider network

At Qkine we are so proud of all the wonderful women we work with! This #InternationalWomensDay we want to celebrate our amazing network and empower #WomenInSTEM to learn from and help each other #empoweringwomen #womenpower

8 03, 2021

Catherine Elton, Qkine founder and CEO, recognised in the #21towatch in 2021

By |2021-03-08T17:47:55+00:00March 8th, 2021|awards, news|Comments Off on Catherine Elton, Qkine founder and CEO, recognised in the #21towatch in 2021

The #21toWatch campaign showcases 7 people, 7 companies and 7 inventions at the forefront of innovation in Cambridge and the East of England. The results were announced on the 4th March and we are delighted that our CEO, Catherine Elton, was named one of the 7 “people” to watch.

25 11, 2020

Qkine, with UK biotechnology companies Manchester BIOGEL and Cellesce, is developing fully synthetic animal-free scaffolds to overcome barriers in sustainable and scalable organoid culture, in a project funded by Innovate UK

By |2020-11-25T15:00:51+00:00November 25th, 2020|animal-free, news, organoid news|Comments Off on Qkine, with UK biotechnology companies Manchester BIOGEL and Cellesce, is developing fully synthetic animal-free scaffolds to overcome barriers in sustainable and scalable organoid culture, in a project funded by Innovate UK

Qkine, Manchester BIOGEL and Cellesce have been awarded Innovate UK Sustainable Innovation Funding to develop fully synthetic, chemically-defined three-dimensional (3D) scaffolds to enable manufacture scale up and improve reproducibility of patient-derived organoids.

11 11, 2020

Qkine shortlisted in the Cambridge Independent 2020 Science & Technology awards

By |2020-11-11T12:05:36+00:00November 11th, 2020|awards, news|Comments Off on Qkine shortlisted in the Cambridge Independent 2020 Science & Technology awards

Qkine is delighted to have been shortlisted in the prestigious Cambridge Independent 2020 Science and Technology Awards. Sponsored by Kao Data, the Startup of the Year shortlist recognises "early-stage companies that show entrepreneurial drive to solve a problem, or improve on what is already out there". Qkine would like to extend its congratulations [...]

9 11, 2020

Organoid Q&A with industry experts from the HUB, CSHL and Stemnovate

By |2020-12-08T16:33:07+00:00November 9th, 2020|organoid news, quality, resources|Comments Off on Organoid Q&A with industry experts from the HUB, CSHL and Stemnovate

We recently held a webinar with CytoSMART and organoid pioneers from Cold Spring Harbor Laboratory, Stemnovate and the Hubrecht Organoid Technology titled: what's needed to realize the potential of organoids? Following presentations from our speakers, we held an insightful Q&A session to address key challenges and questions from the audience. In this blog post, [...]

14 10, 2020

On-demand webinar: What’s needed to realise the potential of organoids?

By |2020-11-10T16:07:01+00:00October 14th, 2020|organoid news, quality, resources|Comments Off on On-demand webinar: What’s needed to realise the potential of organoids?

From standardization of imaging techniques, to more reproducible and cost-effective organoid culture media Organoids have the potential to revolutionize current drug discovery approaches, enhance the physiological relevance of in vitro disease models, and deliver on the promise of precision medicine. But, as with any new technology, there are a number of hurdles to overcome as [...]

Go to Top